报价延迟最少15分钟:2025/09/03 19:24 EDT
盘后时段
|
||||
|
4.92 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.925
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-19.25/-4.44
|
|
企业价值
24.73M
|
| 资产负债 |
|
每股账面净值
-9.48
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/03 19:24 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib. |
